Antiviral Activities of Methylated Nordihydroguaiaretic Acids. 2. Targeting Herpes Simplex Virus Replication by the Mutation Insensitive Transcription Inhibitor Tetra-O-methyl-NDGA
Authors:
- 1 July 1998
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (16) , 3001-3007
Abstract
We had previously reported that tetramethyl-O-NGDA (M4N), a synthetic derivative of the naturally occurring nordihydroguaiaretic acid (NDGA), is able to inhibit HIV Tat transactivation by blocking host Sp1 protein at the Sp1 cognate binding site on the HIV LTR promoter. The present studies were undertaken to examine whether M4N is able to inhibit the replication of herpes simplex virus (HSV), another Sp1-regulated virus. The results showed that in Vero cells, M4N inhibits at micromolar levels (IC50 = 43.5 μM) the expression of the herpes immediate early gene (α-ICP4), which is essential for HSV replication. An electrophoretic mobility shift assay, examining Sp1 binding to the α-ICP4 promoter, showed a significant inhibition of the control bands: 88% inhibition of the fast moving band (FMB) and 45% of the slow moving band (SMB), at 100 μM of drug concentration. Comparative studies between M4N and acycloguanosine (acyclovir, ACV) in cultured Vero cells revealed an interesting pattern in the drug sensitivity (IC50) and cytotoxicity (TC50) parameters. For M4N, the IC50 varied between 11.7 and 4 μM in 10 passages of HSV-1 and 4 passages of HSV-2 with no indication for a requirement of higher drug concentration. In contrast, for acyclovir, the IC50 increased from 7 μM in the first passage to 444 μM in the tenth passage of HSV-1, and >88 μM for the fourth passage of HSV-2, indicating a rapid build-up of drug resistance against acyclovir. While the selective index (SI), defined as the ratio: TC50/IC50, remained relatively constant for M4N; it dropped 60-fold for acyclovir in the endpoints of viral passages. Drug sensitivity for M4N toward the acyclovir-sensitive strain (sm44) and the acyclovir-resistant strain (ACV-10) of HSV-1 was similar, indicating no cross-resistance between M4N and acyclovir in their anti-HSV effects. These results may have an important clinical relevance since HSV has been shown to be a factor for spreading of HIV.Keywords
This publication has 19 references indexed in Scilit:
- Cellular factors as alternative targets for inhibition of HIV-11This review is based on the presentation originally made at the Ninth International Conference on Antiviral Research in Urabandai, Fukushima, Japan, May 19–24, 1996.1Antiviral Research, 1997
- Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patientsAIDS, 1996
- Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatographyJournal of Chromatography A, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Muscle-specific expression of the cardiac alpha-actin gene requires MyoD1, CArG-box binding factor, and Sp1.Genes & Development, 1990
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990
- Analysis of Sp1 in vivo reveals mutiple transcriptional domains, including a novel glutamine-rich activation motifCell, 1988
- Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compoundsJournal of Virological Methods, 1988
- Sp1 binds to promoter sequences and activates herpes simplex virus ‘immediate-early’ gene transcription in vitroNature, 1985
- A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agentsAntiviral Research, 1983